Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | TP53 over exp |
Gene Variant Detail | |
Relevant Treatment Approaches |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT06482684 | Phase II | Ibrutinib Ibrutinib + Rituximab Bendamustine + Ibrutinib + Rituximab Cyclophosphamide + Doxorubicin + Ibrutinib + Prednisone + Rituximab + Vincristine Sulfate Brexucabtagene autoleucel Cisplatin + Cytarabine + Dexamethasone + Rituximab | CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma (CARMAN) | Recruiting | DEU | 0 |